BXL1H5 is a novel monoclonal antibody that binds to TrkA receptors or targets used in developing treatments to tackle pain.
The license for the process involving TrkA receptors has been granted to Glenmarkâs wholly owned subsidiary Glenmark Pharmaceuticals SA (GPSA), the company said.
As part of the agreement, Glenmark will further develop and commercialise BXL1H5 in exchange for an undisclosed upfront and milestone payments to Lay Line Genomics.
The India-based drug maker plans to develop BXL1H5 at its biologics research centre in Switzerland, which focuses on discovering and developing novel biologic entities (NBE).
Glenmark CEO and MD Glenn Saldanha said that the drug firm will leverage its expertise in monoclonal antibodies to progress BXL1H5 rapidly into clinical development.